Serotonergic antidepressant effects on aggressive, self-injurious and destructive/disruptive behaviours in intellectually disabled adults: A retrospective, open-label, naturalistic trial

International Journal of Neuropsychopharmacology

Volumn 8, Issue 1, 2005, Pages 37-48

  Janowsky, David S ^a,c   Shetty, Mahesh ^b   Barnhill, Jarrett ^a,c   Elamir, Belal ^c   Davis, John M ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c Murdoch Center   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Aggression; Antidepressants; Mental retardation; Self injurious behaviour; SSRIs

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; LITHIUM; MESORIDAZINE; OLANZAPINE; PAROXETINE; PROPRANOLOL; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TIOTIXENE; TOPIRAMATE; VALPROATE SEMISODIUM;

ADULT; AGED; AGGRESSION; ARTICLE; AUTOMUTILATION; CLINICAL ARTICLE; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHORIA; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MALADJUSTMENT; MALE; MENTAL DEFICIENCY; PRIORITY JOURNAL; RATING SCALE; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGGRESSION; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CLOMIPRAMINE; COMORBIDITY; FEMALE; HUMANS; INSTITUTIONALIZATION; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; MENTAL RETARDATION; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT CARE TEAM; PSYCHOMETRICS; RETROSPECTIVE STUDIES; SELF-INJURIOUS BEHAVIOR; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS; SOCIAL BEHAVIOR DISORDERS; VIOLENCE;

EID: 15244360488     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S146114570400481X     Document Type: Article

References (26)

1. Aman MG (1999). Atypical antipsychotics in persons with developmental disabilities. MRDD Research Reviews 5, 253-263.
2. Baumeister AA, Sevin JA, King BH (1998). Neuroleptics. In: Reiss S, Aman MG (Eds.), The International Consensus Handbook (pp. 133-150). The Ohio State University.
3. Bodfish JW, Madison JT (1993). Diagnosis and fluoxetine treatment of compulsive behavior disorder of adults with mental retardation. American Journal of Mental Retardation 98, 360-367.
4. Branford D, Bhaumik S, Naik B (1998). Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. Journal of Intellectual Disability Research 43, 301-306.
5. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH (1997). Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. Journal of Child and Adolescent Psychopharmacology 7, 109-121.
6. Cohen S, Underwood MT (1994). The use of clozapine in a mentally retarded and aggressive population. Journal of Clinical Psychiatry 55, 440-444.
7. Davanzo PA, Belin TR, Widawski MH, King BH (1998). Paroxetine treatment of aggression and self-injury in persons with mental retardation. American Journal of Mental Retardation 102, 427-437.
8. Dech B, Budow, L (1991). The use of fluoxetine in an adolescent with Prader-Willi syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 1, 25-40.
9. Fatemi SH, Resalmuto GM, Khan L, Thuras P (1998). Fluoxetine in the treatment of adolescent patients with autism: a longitudinal open trial. Journal of Autism and Developmental Disorders 28, 303-307.
10. Garber HJ, McGonagle JJ, Slomka GT, Monteverde E (1992). Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. Journal of the American Academy of Child and Adolescent Psychiatry 32, 1157-1160.
11. Ghazuiddin M, Tsai L, Ghazuiddin N (1991). Fluoxetine in autism and depression. Journal of the American Academy of Child and Adolescent Psychiatry 30, 508.
12. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry 50, 441-447.
13. Horrigan JP, Barnhill LJ, Courvoisie HE (1997). Olanzapine in PDD. Journal of the American Academy of Child and Adolescent Psychiatry 36, 1166-1167.
14. Janowsky DS, Barnhill LJ, Davis JM (2003). Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults. Journal of Clinical Psychiatry 64, 1258-1265.
15. Lewis MH, Bodfish JW, Powell SB, Golden RN (1995). Clomipramine treatment for stereotypy and related repetitive movement disorders associated with mental retardation. American Journal of Mental Retardation 100, 299-311.
16. Lewis MH, Bodfish JW, Powell SB, Parker DE, Golden RN (1996). Clomipramine treatment for self-injurious behavior of individuals with mental retardation: a double-blind comparison with placebo. American Journal of Mental Retardation 100, 654-665.
17. Lott RS, Kerrick JM, Cohen SA (1996). Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacology Bulletin 32, 721-729.
18. Markowitz PI (1992). Effect of fluoxetine on self-injurious behavior in the developmentally disabled: a preliminary study. Journal of Clinical Psychopharmacology 12, 27-31.
19. Martin A, Loenig K, Scashill L, Bregman J (1999). Open-label Quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology 2, 99-107.
20. McCracken JT, McGouogh J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine 347, 302-303.
21. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry 5, 1001-1008.
22. NIMH (National Institutes of Mental Health) (1985). Clinical Global Impression Scale. Psychopharmacology Bulletin 21, 839-843.
23. Nyhan WL, Johnson HG, Kaufman IA, Jones KL (1980). Serotonergic approaches to the modification of behavior in the Lesch-Nyhan Syndrome. Applied Research in Mental Retardation 1, 25-40.
24. Ricketts RW, Goza AB, Ellis CR, Singh YN, Singh NN, Cooke III JC (1993). Fluoxetine treatment of severe self-injury in young adults with mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry 32, 865-869.
25. Sanchez LE, Campbell M, Small AM, Cueva JE, Armenteros JL, Adams PB (1996). A pilot study of clomipramine in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry 35, 537-544.
26. Varley CK, Holm VA (1990). A two-year followup of autistic children treated with fenfluramine. Journal of the American Academy of Child and Adolescent Psychiatry 29, 137-140.